glp-1 drugs in development GLP-1R Agonists for Weight Loss Long-term Success of GLP-1s Hinges
Description
Wang J, Kim CH
Remember that dose reduction does not erase the progress made at higher levels
has received honoraria for lectures, presentations, and educational events from Eli Lilly & Co
Accessed 09 Jun 2020
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for managing type 2 diabetes mellitus and obesity because of their glucose-lowering, weight-reducing, and cardiovascular benefits
5 This observation supports the notion that signals originating from the gut in response to the oral ingestion of nutrients are instrumental in the stimulation of mealtime insulin release
